Switching among equivalents in chronic cardiovascular therapies: 'real world' data from Italy

Elisabetta Poluzzi, Giacomo Veronese, Carlo Piccinni, Emanuel Raschi, Ariola Koci, Paola Pagano, Brian Godman, Giulio Marchesini, Giuseppe Boriani, Fabrizio De Ponti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Since August 2012, Italian general practitioners are required to prescribe the generic name of medicines, except for refill of chronic therapy. We evaluated the extent of switching among equivalents in chronic cardiovascular therapies, the influence of the 2012 regulatory intervention and of patient-related or drug-related factors. Prescription of off-patent antiarrhythmics, oral antidiabetics, and ACE-inhibitors dispensed from August 2011 to August 2013 within the Bologna Local Health Authority (870,000 inhabitants) were collected. The rate of actual switching among equivalents was evaluated monthly. The effect of the regulatory intervention was estimated by interrupted time series analysis. Adjusted odds ratios (aORs) of switching were calculated for: age, gender, number of different equivalents available for each drug, change in dispensing pharmacy between subsequent refills. The average monthly rates of switches were 9.6%, 16.3%, and 16.3% for antiarrhythmics, antidiabetics, and ACE-inhibitors, respectively. Values significantly increased soon after the regulatory intervention for ACE-inhibitors (+1.81%, p=0.00), antiarrhythmics (+1.46%, p=0.01) and antidiabetics (+1.09%, p=0.01), and no significant decreasing trends were observed in the following 12 months. For all drug classes, odd of switching was higher in case of change in dispensing pharmacy (up to aOR=4.31, 95CI=4.26-4.35 for ACE-inhibitors) and availability of ≥5 different equivalents (up to aOR=7.82, 95CI=7.39-8.28 for antidiabetics). Switching was lower for age ≥65 for antidiabetics and ACE-inhibitors (aOR=0.92, 95CI=0.90-0.93; 0.87, 0.86-0.88, respectively). The Italian regulatory intervention generated an immediate increase, not sustained in time, in switching among equivalents of cardiovascular therapies. Young age, high number of available equivalents and changes in dispensing pharmacy between subsequent refills were associated with switching.
LanguageEnglish
Pages63-69
Number of pages7
JournalBasic and Clinical Pharmacology and Toxicology
Volume118
Issue number1
Early online date2 Aug 2015
DOIs
Publication statusPublished - 1 Jan 2016

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Hypoglycemic Agents
Italy
Pharmaceutical Preparations
Immunoglobulin Class Switching
Therapeutics
General Practitioners
Names
Prescriptions
Time series analysis
Odds Ratio
Medicine
Health
Switches
Availability

Keywords

  • pharmaceutical expenditure
  • cardiovascular therapies
  • generic medicines

Cite this

Poluzzi, E., Veronese, G., Piccinni, C., Raschi, E., Koci, A., Pagano, P., ... De Ponti, F. (2016). Switching among equivalents in chronic cardiovascular therapies: 'real world' data from Italy. Basic and Clinical Pharmacology and Toxicology , 118(1), 63-69. https://doi.org/10.1111/bcpt.12442
Poluzzi, Elisabetta ; Veronese, Giacomo ; Piccinni, Carlo ; Raschi, Emanuel ; Koci, Ariola ; Pagano, Paola ; Godman, Brian ; Marchesini, Giulio ; Boriani, Giuseppe ; De Ponti, Fabrizio. / Switching among equivalents in chronic cardiovascular therapies : 'real world' data from Italy. In: Basic and Clinical Pharmacology and Toxicology . 2016 ; Vol. 118, No. 1. pp. 63-69.
@article{fd6cc7a9e931473e8d0bdd27e159f9fc,
title = "Switching among equivalents in chronic cardiovascular therapies: 'real world' data from Italy",
abstract = "Since August 2012, Italian general practitioners are required to prescribe the generic name of medicines, except for refill of chronic therapy. We evaluated the extent of switching among equivalents in chronic cardiovascular therapies, the influence of the 2012 regulatory intervention and of patient-related or drug-related factors. Prescription of off-patent antiarrhythmics, oral antidiabetics, and ACE-inhibitors dispensed from August 2011 to August 2013 within the Bologna Local Health Authority (870,000 inhabitants) were collected. The rate of actual switching among equivalents was evaluated monthly. The effect of the regulatory intervention was estimated by interrupted time series analysis. Adjusted odds ratios (aORs) of switching were calculated for: age, gender, number of different equivalents available for each drug, change in dispensing pharmacy between subsequent refills. The average monthly rates of switches were 9.6{\%}, 16.3{\%}, and 16.3{\%} for antiarrhythmics, antidiabetics, and ACE-inhibitors, respectively. Values significantly increased soon after the regulatory intervention for ACE-inhibitors (+1.81{\%}, p=0.00), antiarrhythmics (+1.46{\%}, p=0.01) and antidiabetics (+1.09{\%}, p=0.01), and no significant decreasing trends were observed in the following 12 months. For all drug classes, odd of switching was higher in case of change in dispensing pharmacy (up to aOR=4.31, 95CI=4.26-4.35 for ACE-inhibitors) and availability of ≥5 different equivalents (up to aOR=7.82, 95CI=7.39-8.28 for antidiabetics). Switching was lower for age ≥65 for antidiabetics and ACE-inhibitors (aOR=0.92, 95CI=0.90-0.93; 0.87, 0.86-0.88, respectively). The Italian regulatory intervention generated an immediate increase, not sustained in time, in switching among equivalents of cardiovascular therapies. Young age, high number of available equivalents and changes in dispensing pharmacy between subsequent refills were associated with switching.",
keywords = "pharmaceutical expenditure, cardiovascular therapies, generic medicines",
author = "Elisabetta Poluzzi and Giacomo Veronese and Carlo Piccinni and Emanuel Raschi and Ariola Koci and Paola Pagano and Brian Godman and Giulio Marchesini and Giuseppe Boriani and {De Ponti}, Fabrizio",
note = "This is the peer reviewed version of the following article: Poluzzi, E., Veronese, G., Piccinni, C., Raschi, E., Koci, A., Pagano, P., ... De Ponti, F. (2015). Switching among equivalents in chronic cardiovascular therapies: 'real world' data from Italy. Basic and Clinical Pharmacology and Toxicology . 10.1111/bcpt.12442, which has been published in final form at http://dx.doi.org/10.1111/bcpt.12442. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/bcpt.12442",
language = "English",
volume = "118",
pages = "63--69",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
number = "1",

}

Poluzzi, E, Veronese, G, Piccinni, C, Raschi, E, Koci, A, Pagano, P, Godman, B, Marchesini, G, Boriani, G & De Ponti, F 2016, 'Switching among equivalents in chronic cardiovascular therapies: 'real world' data from Italy' Basic and Clinical Pharmacology and Toxicology , vol. 118, no. 1, pp. 63-69. https://doi.org/10.1111/bcpt.12442

Switching among equivalents in chronic cardiovascular therapies : 'real world' data from Italy. / Poluzzi, Elisabetta; Veronese, Giacomo; Piccinni, Carlo; Raschi, Emanuel; Koci, Ariola; Pagano, Paola; Godman, Brian; Marchesini, Giulio; Boriani, Giuseppe; De Ponti, Fabrizio.

In: Basic and Clinical Pharmacology and Toxicology , Vol. 118, No. 1, 01.01.2016, p. 63-69.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Switching among equivalents in chronic cardiovascular therapies

T2 - Basic and Clinical Pharmacology and Toxicology

AU - Poluzzi, Elisabetta

AU - Veronese, Giacomo

AU - Piccinni, Carlo

AU - Raschi, Emanuel

AU - Koci, Ariola

AU - Pagano, Paola

AU - Godman, Brian

AU - Marchesini, Giulio

AU - Boriani, Giuseppe

AU - De Ponti, Fabrizio

N1 - This is the peer reviewed version of the following article: Poluzzi, E., Veronese, G., Piccinni, C., Raschi, E., Koci, A., Pagano, P., ... De Ponti, F. (2015). Switching among equivalents in chronic cardiovascular therapies: 'real world' data from Italy. Basic and Clinical Pharmacology and Toxicology . 10.1111/bcpt.12442, which has been published in final form at http://dx.doi.org/10.1111/bcpt.12442. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Since August 2012, Italian general practitioners are required to prescribe the generic name of medicines, except for refill of chronic therapy. We evaluated the extent of switching among equivalents in chronic cardiovascular therapies, the influence of the 2012 regulatory intervention and of patient-related or drug-related factors. Prescription of off-patent antiarrhythmics, oral antidiabetics, and ACE-inhibitors dispensed from August 2011 to August 2013 within the Bologna Local Health Authority (870,000 inhabitants) were collected. The rate of actual switching among equivalents was evaluated monthly. The effect of the regulatory intervention was estimated by interrupted time series analysis. Adjusted odds ratios (aORs) of switching were calculated for: age, gender, number of different equivalents available for each drug, change in dispensing pharmacy between subsequent refills. The average monthly rates of switches were 9.6%, 16.3%, and 16.3% for antiarrhythmics, antidiabetics, and ACE-inhibitors, respectively. Values significantly increased soon after the regulatory intervention for ACE-inhibitors (+1.81%, p=0.00), antiarrhythmics (+1.46%, p=0.01) and antidiabetics (+1.09%, p=0.01), and no significant decreasing trends were observed in the following 12 months. For all drug classes, odd of switching was higher in case of change in dispensing pharmacy (up to aOR=4.31, 95CI=4.26-4.35 for ACE-inhibitors) and availability of ≥5 different equivalents (up to aOR=7.82, 95CI=7.39-8.28 for antidiabetics). Switching was lower for age ≥65 for antidiabetics and ACE-inhibitors (aOR=0.92, 95CI=0.90-0.93; 0.87, 0.86-0.88, respectively). The Italian regulatory intervention generated an immediate increase, not sustained in time, in switching among equivalents of cardiovascular therapies. Young age, high number of available equivalents and changes in dispensing pharmacy between subsequent refills were associated with switching.

AB - Since August 2012, Italian general practitioners are required to prescribe the generic name of medicines, except for refill of chronic therapy. We evaluated the extent of switching among equivalents in chronic cardiovascular therapies, the influence of the 2012 regulatory intervention and of patient-related or drug-related factors. Prescription of off-patent antiarrhythmics, oral antidiabetics, and ACE-inhibitors dispensed from August 2011 to August 2013 within the Bologna Local Health Authority (870,000 inhabitants) were collected. The rate of actual switching among equivalents was evaluated monthly. The effect of the regulatory intervention was estimated by interrupted time series analysis. Adjusted odds ratios (aORs) of switching were calculated for: age, gender, number of different equivalents available for each drug, change in dispensing pharmacy between subsequent refills. The average monthly rates of switches were 9.6%, 16.3%, and 16.3% for antiarrhythmics, antidiabetics, and ACE-inhibitors, respectively. Values significantly increased soon after the regulatory intervention for ACE-inhibitors (+1.81%, p=0.00), antiarrhythmics (+1.46%, p=0.01) and antidiabetics (+1.09%, p=0.01), and no significant decreasing trends were observed in the following 12 months. For all drug classes, odd of switching was higher in case of change in dispensing pharmacy (up to aOR=4.31, 95CI=4.26-4.35 for ACE-inhibitors) and availability of ≥5 different equivalents (up to aOR=7.82, 95CI=7.39-8.28 for antidiabetics). Switching was lower for age ≥65 for antidiabetics and ACE-inhibitors (aOR=0.92, 95CI=0.90-0.93; 0.87, 0.86-0.88, respectively). The Italian regulatory intervention generated an immediate increase, not sustained in time, in switching among equivalents of cardiovascular therapies. Young age, high number of available equivalents and changes in dispensing pharmacy between subsequent refills were associated with switching.

KW - pharmaceutical expenditure

KW - cardiovascular therapies

KW - generic medicines

UR - http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291742-7843

U2 - 10.1111/bcpt.12442

DO - 10.1111/bcpt.12442

M3 - Article

VL - 118

SP - 63

EP - 69

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 1

ER -